Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines.

International journal of molecular sciences - 14 Nov 2019

Lentsch Eva, Li Lifei, Pfeffer Susanne, Ekici Arif B, Taher Leila, Pilarsky Christian, Grützmann Robert

Abstract excerpt

In 90% of pancreatic ductal adenocarcinoma cases, genetic alteration of the proto-oncogene Kras has occurred, leading to uncontrolled proliferation of cancerous cells. Targeting Kras has proven to be difficult and the battle against pancreatic cancer is ongoing. A promising approach to combat cancer was the discovery of the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Editing

Share to Gene Knockout Techniques

Share to Gene Targeting

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 31739488
DOI: 10.3390/ijms20225706
PMCID: PMC6888344

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines.PMID 31739488Read ↗

CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlookSemantic proximity Read ↗

CRISPR and KRAS: a match yet to be made.Semantic proximity Read ↗

A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.Semantic proximity Read ↗

Efficacy of CRISPR-Cas9 Gene Editing for Targeting KRAS Mutations in Pancreatic Cancer: A systematic reviewSemantic proximity Read ↗

Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression.Semantic proximity Read ↗

Survival of pancreatic cancer cells lacking KRAS functionSemantic proximity Read ↗

Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells.Semantic proximity Read ↗

CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancersSemantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells.Semantic proximity Read ↗

Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth.Semantic proximity Read ↗

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.